Literature DB >> 27994925

Acute Eosinophilic Pneumonia with Respiratory Failure Induced by Synthetic Cannabinoid Inhalation.

Nesrin Öcal1, Deniz Doğan1, Ali Fuat Çiçek2, Orhan Yücel1, Ergun Tozkoparan1.   

Abstract

BACKGROUND: In recent days, synthetic cannabinoid derivatives have become life threatening for young people. Here, we want to share a case of acute eosinophilic pneumonia triggered by inhalation of synthetic cannabinoid, new side effects of which are being detected day by day. CASE REPORT: A 21-year-old male, who had no history of pulmonary diseases, was admitted to the clinic with shortness of breath. His oxygen saturation was measured as 85-86% in room air. Common irregular ground-glass opacities were observed in thorax radiology. His peripheral blood eosinophil count was 1100 cell/mm3 with a leukocyte differential of 12%. Sputum eosinophilia was also observed. The patient was diagnosed with acute eosinophilic pneumonia in terms of current clinical, radiological and laboratory findings. Rapid remission was achieved with corticosteroid therapy.
CONCLUSION: This is the first reported case of acute eosinophilic pneumonia induced by synthetic cannabinoid inhalation.

Entities:  

Keywords:  Acute eosinophilic pneumonia; sputum eosinophilia; synthetic cannabinoid

Year:  2016        PMID: 27994925      PMCID: PMC5156457          DOI: 10.5152/balkanmedj.2016.151145

Source DB:  PubMed          Journal:  Balkan Med J        ISSN: 2146-3123            Impact factor:   2.021


  8 in total

1.  Synthetic cannabinoid exposures reported to Texas poison centers.

Authors:  Mathias B Forrester; Kurt Kleinschmidt; Evan Schwarz; Amy Young
Journal:  J Addict Dis       Date:  2011-10

2.  Clinical implications of initial peripheral eosinophilia in acute eosinophilic pneumonia.

Authors:  Byung Woo Jhun; Se Jin Kim; Kang Kim; Ji Eun Lee
Journal:  Respirology       Date:  2014-07-02       Impact factor: 6.424

3.  Phenytoin-induced acute respiratory failure with pulmonary eosinophilia.

Authors:  M Mahatma; E F Haponik; S Nelson; A Lopez; W R Summer
Journal:  Am J Med       Date:  1989-07       Impact factor: 4.965

4.  Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.

Authors:  Maren Hermanns-Clausen; Stefan Kneisel; Bela Szabo; Volker Auwärter
Journal:  Addiction       Date:  2012-11-01       Impact factor: 6.526

5.  Acute eosinophilic pneumonia: radiologic and clinical features.

Authors:  M A King; A L Pope-Harman; J N Allen; G A Christoforidis; A J Christoforidis
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

6.  Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Center dust.

Authors:  William N Rom; Michael Weiden; Roberto Garcia; Ting An Yie; Pratan Vathesatogkit; Doris B Tse; Georgeann McGuinness; Victor Roggli; David Prezant
Journal:  Am J Respir Crit Care Med       Date:  2002-09-15       Impact factor: 21.405

7.  URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products.

Authors:  Nahoko Uchiyama; Maiko Kawamura; Ruri Kikura-Hanajiri; Yukihiro Goda
Journal:  Forensic Sci Int       Date:  2012-10-09       Impact factor: 2.395

Review 8.  Pulmonary eosinophilic syndromes.

Authors:  Michael E Wechsler
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

  8 in total
  3 in total

Review 1.  Designer drugs: mechanism of action and adverse effects.

Authors:  Dino Luethi; Matthias E Liechti
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

Review 2.  Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier.

Authors:  Cristian Scheau; Constantin Caruntu; Ioana Anca Badarau; Andreea-Elena Scheau; Anca Oana Docea; Daniela Calina; Ana Caruntu
Journal:  J Pers Med       Date:  2021-05-31

3.  Expression and Functions of the CB2 Receptor in Human Leukocytes.

Authors:  Mélissa Simard; Volatiana Rakotoarivelo; Vincenzo Di Marzo; Nicolas Flamand
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.